Strategies for management of Clostridium difficile infection in immunosuppressed patients

Gastroenterology and Hepatology

Volumn 7, Issue 11, 2011, Pages 750-752

  Binion, David G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

BACTERIUM CARRIER; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC PROCEDURES; DISEASE COURSE; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG EFFICACY; ENDOSCOPY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HAND WASHING; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; NONHUMAN; NOTE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; TREATMENT INDICATION;

EID: 84855670776     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:589-600.
2. Sinh P, Barrett TA, Yun L. Clostridium difficile infection and inflammatory bowel disease: a review. Gastroenterol Res Pract. 2011;2011:136064.
3. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976-983.
4. Hardesty JS, Juang P. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. Pharmacotherapy. 2011;31:877-886.
5. Ben-Horin S, Margalit M, Bossuyt P, et al European Crohn's and Colitis Organization (ECCO). Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010;4:194-198.